Why the study?
Can carotid artery intima-media thickness (IMT) be used as an intermediate endpoint in antihypertensive treatment trials?
Can carotid artery intima-media thickness (IMT) be used as an intermediate endpoint in antihypertensive treatment trials?
Carotid IMT measured by B-mode ultrasound is a valid surrogate endpoint for evaluating the efficacy of antihypertensive therapies on cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Supports IMT evaluation as trial surrogate; leaves open validation before guiding hypertension management.
Alberto Zanchetti (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: